Assembly Biosciences

About Assembly Assembly Biosciences, Inc. is a biopharmaceutical company developing novel therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's proprietary Core Protein Allosteric Modulators (CpAMs) are small molecule, oral agents for the treatment of viral infections. The company's lead program focuses on hepatitis B (HBV), which infects an estimated 350 million people worldwide and is associated with 600,000 deaths annually. CpAMs alter the HBV core protein, a unique target that is essential to the functioning of the virus. Unlike current therapies that only suppress HBV, CpAMs may have curative potential. Assembly also is developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections.
Company Growth (employees)
Type
Public
HQ
New York, US
Founded
2007
Size (employees)
51 (est)
Assembly Biosciences was founded in 2007 and is headquartered in New York, US

Assembly Biosciences Office Locations

Assembly Biosciences has offices in New York, Carmel, Bloomington and San Francisco
New York, US (HQ)
101 Sixth Avenue 9th Floor
San Francisco, US
409 Illinois St
Bloomington, US
212 S. Hawthorne Drive
Carmel, US
310 11711 N Meridian St

Assembly Biosciences Data and Metrics

Assembly Biosciences Financial Metrics

USD

Net income (Q1, 2017)

(13.9 m)

EBIT (Q1, 2017)

(13.9 m)

Market capitalization (21-Jul-2017)

377.3 m

Cash (31-Mar-2017)

70.8 m
Assembly Biosciences's current market capitalization is $377.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

33.1 m

General and administrative expense

12.2 m

Operating expense total

24 m29.7 m45.3 m

EBIT

(98.2 m)(24 m)(29.7 m)(45.3 m)

Pre tax profit

(44.9 m)

Income tax expense

617.7 k

Net Income

(111.7 m)(23.8 m)(28.5 m)(44.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

1.1 m3.7 m3.8 m4.7 m4.6 m8.1 m7.5 m8.8 m10.6 m

General and administrative expense

1.4 m7.4 m3.4 m2.5 m2.5 m3.2 m2.9 m2.8 m4 m

Operating expense total

2.5 m11.1 m7.2 m7.2 m7.1 m11.3 m10.5 m11.7 m14.6 m

EBIT

(2.5 m)(11.1 m)(7.2 m)(7.2 m)(7.1 m)(11.3 m)(10.5 m)(11.7 m)(13.9 m)

Interest income

36.9 k35.2 k58.3 k

Net Income

(2.5 m)(11 m)(7.1 m)(6.9 m)(6.6 m)(11 m)(10.2 m)(11.6 m)(13.9 m)
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

81.3 k14.6 m37 m20.5 m27.1 m29.1 m27.1 m28.6 m

Inventories

611.2 k

Current Assets

27.1 m29.2 m68.4 m53.6 m

PP&E

156.4 k148.6 k214.7 k

Goodwill

12.7 m12.6 m12.6 m

Total Assets

27.1 m71.2 m133.7 m98.1 m

Accounts Payable

2.6 m907.6 k1.4 m2.4 m

Current Liabilities

1.1 m3.4 m7.1 m

Non-Current Liabilities

11.6 m11.1 m

Total Liabilities

15 m18.2 m

Additional Paid-in Capital

135.8 m194.1 m283.5 m288.7 m

Retained Earnings

(135.5 m)(164 m)(208.2 m)

Total Equity

24.5 m58.6 m118.7 m79.9 m

Financial Leverage

1.1 x1.2 x1.1 x1.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

21.3 m17.9 m96.1 m53.5 m36.4 m20.4 m20.3 m23.8 m70.8 m

Current Assets

21.7 m18.1 m96.3 m71.3 m66.5 m59.1 m64.1 m59.3 m92.2 m

PP&E

173.2 k174 k156.5 k132.2 k113.7 k128.5 k182.8 k

Goodwill

12.1 m12.7 m12.6 m12.6 m12.6 m12.6 m12.6 m12.6 m

Total Assets

21.8 m60.4 m138.3 m144.7 m139.7 m124.5 m117.2 m109.1 m134.3 m

Accounts Payable

1.4 m1 m1.3 m1.3 m1.5 m2.3 m2.4 m3.8 m1.9 m

Current Liabilities

1.5 m1 m2.1 m2.2 m2.7 m3.6 m5 m7.5 m11 m

Non-Current Liabilities

11.6 m11.6 m11.6 m11.6 m11.6 m55.4 m

Additional Paid-in Capital

138.2 m176.1 m267.3 m280.6 m282 m285 m286.5 m287.5 m290.6 m

Retained Earnings

(118.3 m)(129.3 m)(142.7 m)(149.6 m)(156.2 m)(175 m)(185.1 m)(196.7 m)(222.2 m)

Total Equity

20.3 m47.2 m124.6 m130.9 m125.4 m109.3 m100.6 m90 m67.9 m

Financial Leverage

1.1 x1.3 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(19.4 m)(23.8 m)(28.5 m)(44.3 m)

Depreciation and Amortization

6.2 k11 k65 k80.3 k

Inventories

93.1 k

Accounts Payable

(107.4 k)(2.5 m)456.1 k1 m

Cash From Operating Activities

(17.8 m)(15 m)(18.7 m)(34.9 m)

Purchases of PP&E

(150 k)(58.3 k)

Cash From Investing Activities

(6.5 k)277.4 k(64.9 m)36.2 m

Cash From Financing Activities

24.4 m16.7 m81.6 m152.6 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.5 m)(11 m)(7.1 m)(6.9 m)(6.6 m)(11 m)(10.2 m)(11.6 m)(13.9 m)

Accounts Payable

1.4 m1 m1.3 m1.3 m1.5 m2.3 m2.4 m3.8 m1.9 m
Y, 2017

Financial Leverage

2 x

Assembly Biosciences Market Value History

Assembly Biosciences Company Life and Culture

You may also be interested in